Researchers hope their findings could lead to targeted interventions to improve cognitive outcomes in pediatric brain tumor survivors from families with low socioeconomic status.
Ajai Chari, MD, of Mount Sinai Hospital in New York City, provides his perspective on the current state of care in multiple myeloma.
Photobiomodulation shows impressive results in pretrial use for treatment and prevention of treatment-associated mucositis in pediatric patients.
Investigators assessed disparities in patient access to therapies approved for the treatment of gastrointestinal malignancies in the United States, the United Kingdom, Europe, and Ireland, as well as benefit relative to cost.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
Late diagnosis of breast cancer significantly impacts survival — and men are generally diagnosed with breast cancer at more advanced stages.
Phase 3 clinical trial of paclitaxel and atezolizumab shows no significant survival benefit, but questions remain over FDA decision to issue safety alert.
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
Phase 2 clinical trial shows promising result for dabrafenib and trametinib combination in patients with advanced cholangiocarcinoma with a BRAFV600E mutation.
